Xiuman N. Zhou
Shenzhen, 518107, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
A Bispecific Peptide-Drug Conjugate Targeting LAG-3 and PD-L1 Harnesses Antitumor Immunity of Macrophages and T Cells.
Journal: Journal of medicinal chemistry
Published: March 20, 2026
DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 28, 2025
VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: December 18, 2024
In vitro screening methods of novel immune checkpoint inhibitors related to T cell infiltration and anti-PD-1 resistance.
Journal: Methods in cell biology
Published: November 08, 2024
Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.
Journal: Cancer immunology, immunotherapy : CII
Published: October 08, 2024
A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis.
Journal: Cancer immunology, immunotherapy : CII
Published: August 27, 2024
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy.
Journal: Nature communications
Published: July 05, 2024
Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy.
Journal: BMC biology
Published: May 08, 2024
Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: April 22, 2024
Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.
Journal: Biochemical pharmacology
Published: January 21, 2024
Last Updated: 09/26/2026